WO2008115259A3 - Derivatives of benzoxadiazole suitable for the treatment of cell proliferative diseases - Google Patents
Derivatives of benzoxadiazole suitable for the treatment of cell proliferative diseases Download PDFInfo
- Publication number
- WO2008115259A3 WO2008115259A3 PCT/US2007/075511 US2007075511W WO2008115259A3 WO 2008115259 A3 WO2008115259 A3 WO 2008115259A3 US 2007075511 W US2007075511 W US 2007075511W WO 2008115259 A3 WO2008115259 A3 WO 2008115259A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ubiquitination
- pharmaceutical compositions
- compounds
- treatment
- useful
- Prior art date
Links
- SLLFVLKNXABYGI-UHFFFAOYSA-N 1,2,3-benzoxadiazole Chemical class C1=CC=C2ON=NC2=C1 SLLFVLKNXABYGI-UHFFFAOYSA-N 0.000 title 1
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 230000002062 proliferating effect Effects 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 5
- 239000008194 pharmaceutical composition Substances 0.000 abstract 5
- 230000034512 ubiquitination Effects 0.000 abstract 4
- 238000010798 ubiquitination Methods 0.000 abstract 4
- 239000003112 inhibitor Substances 0.000 abstract 2
- 230000005764 inhibitory process Effects 0.000 abstract 2
- 102000003714 TNF receptor-associated factor 6 Human genes 0.000 abstract 1
- 108090000009 TNF receptor-associated factor 6 Proteins 0.000 abstract 1
- 102000044159 Ubiquitin Human genes 0.000 abstract 1
- 108090000848 Ubiquitin Proteins 0.000 abstract 1
- 229940127507 Ubiquitin Ligase Inhibitors Drugs 0.000 abstract 1
- 102000006275 Ubiquitin-Protein Ligases Human genes 0.000 abstract 1
- 108010083111 Ubiquitin-Protein Ligases Proteins 0.000 abstract 1
- 230000008238 biochemical pathway Effects 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000019491 signal transduction Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/08—1,2,5-Oxadiazoles; Hydrogenated 1,2,5-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
This invention describes compounds and pharmaceutical compositions useful as ubiquitin agent inhibitors, particularly ubiquitin ligase inhibitors. The compounds and pharmaceutical compositions of the invention are useful as inhibitors of the biochemical pathways of organisms in which ubiquitination is involved, such as signal transduction pathways. The invention also comprises the use of the compounds and pharmaceutical compositions of the invention for the treatment of conditions that require inhibition of ubiquitination. Furthermore, the invention comprises methods of inhibiting ubiquitination in a cell comprising contacting a cell in which inhibition of ubiquitination is desired with a compound or pharmaceutical composition according to the invention. Particularly, the compounds and pharmaceutical compositions are useful to inhibit the ubiquitin ligase activity of TRAF6.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US82205006P | 2006-08-10 | 2006-08-10 | |
| US60/822,050 | 2006-08-10 | ||
| US88758507P | 2007-01-31 | 2007-01-31 | |
| US60/887,585 | 2007-01-31 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2008115259A2 WO2008115259A2 (en) | 2008-09-25 |
| WO2008115259A3 true WO2008115259A3 (en) | 2008-12-18 |
Family
ID=39708865
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US2007/075511 WO2008115259A2 (en) | 2006-08-10 | 2007-08-08 | Derivatives of benzoxadiazole suitable for the treatment of cell proliferative diseases |
Country Status (1)
| Country | Link |
|---|---|
| WO (1) | WO2008115259A2 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108658962B (en) * | 2017-03-30 | 2021-10-01 | 复旦大学 | 3-Substituted coumarin furoxan derivatives and their use in the preparation of anti-multidrug-resistant tumor drugs |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA99448C2 (en) | 2006-11-27 | 2012-08-27 | Х. Луннбэк А/С | Heteroaryl amide derivatives |
| EP3768678A1 (en) * | 2018-03-22 | 2021-01-27 | Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt (GmbH) | Traf 6 inhibitors |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006002284A1 (en) * | 2004-06-22 | 2006-01-05 | Rigel Pharmaceuticals, Inc. | Ubiquitin ligase inhibitors |
-
2007
- 2007-08-08 WO PCT/US2007/075511 patent/WO2008115259A2/en active Application Filing
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2006002284A1 (en) * | 2004-06-22 | 2006-01-05 | Rigel Pharmaceuticals, Inc. | Ubiquitin ligase inhibitors |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108658962B (en) * | 2017-03-30 | 2021-10-01 | 复旦大学 | 3-Substituted coumarin furoxan derivatives and their use in the preparation of anti-multidrug-resistant tumor drugs |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008115259A2 (en) | 2008-09-25 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2005007621A3 (en) | Ubiquitin ligase inhibitors | |
| WO2005037845A8 (en) | Benzothiazole and thiazole[5,5-b] pyridine compositions and their use as ubiquitin ligase inhibitors | |
| WO2007095124A3 (en) | Benzazole derivatives, compositions, and methods of use as aurora kinase inhibitors | |
| WO2008013838A3 (en) | Pyridizinone derivatives | |
| EP2573069A3 (en) | Inhibitors of histone deacetylase and prodrugs thereof | |
| WO2008055068A8 (en) | Inhibitors of histone deacetylase | |
| WO2007089634A3 (en) | Inhibitors of fatty acid synthase (fas) | |
| WO2006113919A3 (en) | Aryl alkyl acid derivatives for and use thereof | |
| WO2007109178A3 (en) | Indole derivatives as inhibitors of histone deacetylase | |
| WO2007097931A3 (en) | Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes | |
| WO2007136603A3 (en) | Aminotetrahydropyrans as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes | |
| WO2007011760A3 (en) | Inhibitors of mitotic kinesin | |
| WO2009097113A3 (en) | Oxazole and thiazole compounds as b-catenin modulators and uses thereof | |
| WO2007092213A3 (en) | Inhibitors of e1 activating enzyme | |
| WO2005111039A3 (en) | Compounds and methods for inhibiting mitotic progression by inhibition of aurora kinase | |
| WO2008049123A3 (en) | 2,4-pyrimidinediamine derivatives as inhibitors of jak kinases for the treatment of autoimmune diseases | |
| WO2006078752A3 (en) | Inhibitors of dna methyltransferase | |
| WO2008021038A3 (en) | Pyridobenzazepine compounds and methods for inhibiting mitotic progression | |
| NO20092569L (en) | Inhibitors of Akt activity | |
| WO2008019124A8 (en) | Heteroaryl compounds useful as inhibitors of e1 activating enzymes | |
| WO2007087231A3 (en) | Aminocyclohexanes as dipeptidyl peptidase-iv inhibitors for the treatment or prevention of diabetes | |
| WO2010009139A3 (en) | Imidazolylpyrimidine compounds as hdac and / or cdk inhibitors | |
| WO2006123113A3 (en) | Pyrazolylaminopyrimidine derivatives useful as tyrosine kinase inhibitors | |
| WO2006091395A3 (en) | Inhibitors of akt activity | |
| WO2008118391A3 (en) | Triazinone and diazinone derivatives useful as hsp90 inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07874455 Country of ref document: EP Kind code of ref document: A2 |
|
| NENP | Non-entry into the national phase |
Ref country code: DE |
|
| NENP | Non-entry into the national phase |
Ref country code: RU |
|
| 122 | Ep: pct application non-entry in european phase |
Ref document number: 07874455 Country of ref document: EP Kind code of ref document: A2 |